Printer Friendly

NEW DRUGS FOR TREATMENT OF EDEMA AND HYPERTENSION APPROVED FOR MARKETING

 ROCKVILLE, Md., Sept. 7 /PRNewswire/ -- The first in a new class of loop diuretic compounds for the treatment of edema and hypertension in 10 years has received approval for marketing in the United States, according to Boehringer Mannheim Pharmaceuticals Corporation.
 The product will be marketed under the brand name DEMADEX(TM) (torsemide) in both tablet and injectable form. This is the first NDA approval for the nine-year-old Rockville, Maryland-based company, which will market the product in the United states.
 Both forms of DEMADEX(TM) are indicated for the treatment of excess body fluids (edema) associated with congestive heart failure (CHF), renal disease and hepatic disease. They also are indicated for the treatment of hypertension alone or in combination with other antihypertensive agents.
 In both the United States and European clinical trials, patients with CHF, renal disease, and hepatic disease who received DEMADEX(TM) once daily achieved significant reductions in body weight and excess body fluids when compared to patients who received placebo. In antihyertensive trials, patients taking low dose DEMADEX(TM) showed significant reductions in both systolic and diastolic blood pressure.
 DEMADEX(TM) is highly bioavailable. No dosage adjustments are required for elderly patients or in patients with hepatic disease. Side effects seen were generally transient and included dizziness, headache, nausea and weakness.
 Boehringer Mannheim International, the worldwide company, has been a leader in the European pharmaceutical industry for more than 100 years. Torsemide is currently marketed in Germany under the brand name Unat(R) by Boehringer Mannheim, GmbH.
 The U.S. company already is represented in the cardiovascular market with its copromotion with Wyeth-Ayerst of the antianginal drug ISMO(R) (isosorbide mononitrate). With the approval of DEMADEX(TM), Boehringer Mannheim Pharmaceuticals supports the parent company's commitment to develop and market important new therapies for cardiovascular, metabolic, and oncologic diseases.
 -0- 9/7/93
 /CONTACT: Jennifer Yentema of McAdams Public Relations, 212-698-1503/


CO: Boehringer Mannheim Pharmaceuticals ST: Maryland IN: MTC SU: PDT

TM -- NY076 -- 9568 09/07/93 20:14 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 7, 1993
Words:331
Previous Article:THE MEXICO FUND, INC. DECLARES DIVIDEND
Next Article:UNIVERSAL PICTURES CANCELS PLANS TO FILM ON LOWER ROGUE
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters